Table 3.
Frequencies of predicted diplotypes known to affect warfarin dose in the CANHR and SCF datasets.
| CANHR Diplotype Frequencies | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| VKORC1 diplotype | CYP2C9 diplotype | |||||||||
| *1/*1 | *1/*2 | *1/*3 | *2/*2 | *1/M1L | *1/N218I | *1/*29 | M1L/M1L | *3/M1L | Total | |
| Low dose homozygous (AT/AT) | 153 | 1 | 6 | 0 | 25 | 20 | 12 | 2 | 3 | 222 |
| Low dose heterozygous (AT/GC) | 77 | 0 | 3 | 1 | 13 | 6 | 1 | 1 | 0 | 102 |
| High dose homozygous (GC/GC) | 17 | 1 | 2 | 0 | 4 | 1 | 0 | 1 | 0 | 26 |
| Total | 247 | 2 | 11 | 1 | 42 | 27 | 13 | 4 | 3 | 350 |
| SCF Diplotype Frequencies | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| VKORC1 diplotype | CYP2C9 diplotype | |||||||||
| *1/*1 | *1/*2 | *1/*3 | *2/*2 | *1/M1L | *1/N218I | *2/N218I | *2/*3 | *3/*3 | Total | |
| Low dose homozygous (AT/AT) | 101 | 10 | 5 | 0 | 4 | 3 | 0 | 1 | 0 | 124 |
| Low dose heterozygous (AT/GC) | 145 | 15 | 10 | 1 | 1 | 5 | 1 | 0 | 1 | 179 |
| High dose homozygous (GC/GC) | 41 | 7 | 5 | 0 | 1 | 1 | 0 | 1 | 0 | 56 |
| Total | 287 | 32 | 20 | 1 | 6 | 9 | 1 | 2 | 1 | 359 |
Diplotypes of VKORC1 and CYP2C9 were calculated from observed 1173 and -1639-containing high and low dose VKORC1 haplotypes, and CYP2C9 *1, *2, *3 and the M1L, N218I, and P279T genotypes, assuming no LD between CYP2C9 variants.